Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy LIDDS Interim report Jan – Jun 2021
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr LIDDS carry out a directed share issue of and is provided with approximately MSEK 45Company Analysis
Photo Library
Video Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comFinancial Calendar
Subscribe for news
Press releases
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy LIDDS Interim report Jan – Jun 2021 LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
press
analysis
